The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol.
Arabs
Cardiovascular Diseases
Cholesterol, LDL
Diabetes Mellitus
Risk Factors
Triglycerides
Journal
Oman medical journal
ISSN: 1999-768X
Titre abrégé: Oman Med J
Pays: Oman
ID NLM: 101526350
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
16
02
2022
accepted:
20
02
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
23
4
2022
Statut:
epublish
Résumé
We sought to estimate the percentage achievements of non-high-density lipoprotein cholesterol (non-HDL-C) target in patients with very high atheroscleroticcardiovascular diseases (ASCVD) risk stratified by triglyceride (TG) levels despite statin-controlled low-density lipoprotein cholesterol (LDL-C) in the Centralized Pan-Middle East Survey on the under treatment of hypercholesterolemia. The non-HDL-C target achievement in patients with diabetes mellites (DM) and patients with established ASCVD was defined according to European Society of Cardiology and European Atherosclerosis Society 2019 guidelines for managing dyslipidemia. Patients were stratified to controlled LDL-C defined as < 70 mg/dL (< 1.8 mmol/L) with normal TG < 150 mg/dL (< 1.7 mmol/L) and high TG between 150-400 mg/dL (1.7-4.5 mmol/L). The mean age of our cohort was 58.0±11.0 years, 6.8% (n = 717) were male, 9.7% (104) were smokers, and 48.4% (n = 518) had body mass index of ≥ 30 kg/m A large proportion of statin-controlled LDL-C diabetic patients and patients with established ASCVD with high TGs did not achieve the non-HDL-C target. Our study did not demonstrate an association between ASCVD and high TG levels; and therefore, a follow-up study is highly required to assess long-term ASCVD outcomes in this cohort.
Identifiants
pubmed: 35449790
doi: 10.5001/omj.2022.79
pii: OMJ-37-02-2200023
pmc: PMC9013408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e367Informations de copyright
The OMJ is Published Bimonthly and Copyrighted 2022 by the OMSB.
Références
Curr Vasc Pharmacol. 2016;14(4):374-81
pubmed: 26496982
Diabetes Obes Metab. 2019 Feb;21(2):366-371
pubmed: 30225881
J Clin Lipidol. 2018 May - Jun;12(3):685-692.e2
pubmed: 29574074
Eur Heart J. 2011 Jun;32(11):1345-61
pubmed: 21531743
Circulation. 2002 Nov 12;106(20):2526-9
pubmed: 12427645
N Engl J Med. 2010 Apr 29;362(17):1563-74
pubmed: 20228404
J Clin Lipidol. 2014 Sep-Oct;8(5):473-88
pubmed: 25234560
Angiology. 2014 Nov;65(10):919-26
pubmed: 24301426
J Am Coll Cardiol. 2015 Jun 2;65(21):2267-75
pubmed: 26022813
J Am Coll Cardiol. 2021 Mar 23;77(11):1439-1450
pubmed: 33736827
J Am Coll Cardiol. 2008 Feb 19;51(7):724-30
pubmed: 18279736
J Clin Lipidol. 2014 Jan-Feb;8(1):29-60
pubmed: 24528685
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Diabetes Care. 2009 Mar;32(3):493-8
pubmed: 18984774
Circulation. 2007 Jan 30;115(4):450-8
pubmed: 17190864
Angiology. 2017 Jul;68(6):508-512
pubmed: 27784731
Circulation. 2021 Jan 5;143(1):33-44
pubmed: 33148016
Eur Heart J. 2013 Jun;34(24):1826-33
pubmed: 23248205
Int J Cardiol. 2016 Dec 15;225:268-283
pubmed: 27741487
Heart Views. 2017 Apr-Jun;18(2):41-46
pubmed: 28706594
J Clin Lipidol. 2016 Mar-Apr;10(2):368-77
pubmed: 27055968
Atherosclerosis. 2022 Feb;343:28-50
pubmed: 35091265
Heart Lung Circ. 2016 Oct;25(10):975-81
pubmed: 27634241
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
pubmed: 21487090